Free Trial
NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

Alnylam Pharmaceuticals logo
$245.44 +6.57 (+2.75%)
(As of 12/20/2024 05:31 PM ET)

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Key Stats

Today's Range
$235.93
$247.21
50-Day Range
$232.27
$300.55
52-Week Range
$141.98
$304.39
Volume
1.65 million shs
Average Volume
861,361 shs
Market Capitalization
$31.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$298.09
Consensus Rating
Moderate Buy

Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
87th Percentile Overall Score

ALNY MarketRank™: 

Alnylam Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 133rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 18 buy ratings, 5 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Alnylam Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alnylam Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($2.21) to ($2.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alnylam Pharmaceuticals is -93.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alnylam Pharmaceuticals is -93.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    2.63% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Alnylam Pharmaceuticals has recently decreased by 9.36%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Alnylam Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Alnylam Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.63% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Alnylam Pharmaceuticals has recently decreased by 9.36%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Alnylam Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Alnylam Pharmaceuticals this week, compared to 11 articles on an average week.
  • Search Interest

    Only 2 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,540,455.00 in company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alnylam Pharmaceuticals' insider trading history.
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Stock News Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at StockNews.com
Biotech CEO on RNAI and Medicine of the Future
Leerink Partners Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
See More Headlines

ALNY Stock Analysis - Frequently Asked Questions

Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of 2024. Since then, ALNY stock has increased by 28.2% and is now trading at $245.44.
View the best growth stocks for 2024 here
.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.36. The business's quarterly revenue was down 33.3% on a year-over-year basis.

Top institutional investors of Alnylam Pharmaceuticals include Baillie Gifford & Co. (3.79%), Geode Capital Management LLC (1.66%), Groupama Asset Managment (1.18%) and Bellevue Group AG (0.63%). Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Akshay Vaishnaw, Michael W Bonney, Pushkal Garg, Kevin Joseph Fitzgerald, Tolga Tanguler, Amy W Schulman, Steven M Paul, Dennis A Ausiello, David E I Pyott and Indrani Lall Franchini.
View institutional ownership trends
.

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), AUO (AUOTY), DiamondRock Hospitality (DRH) and The RMR Group (RMR).

Company Calendar

Last Earnings
10/31/2024
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$298.09
High Stock Price Target
$400.00
Low Stock Price Target
$159.00
Potential Upside/Downside
+21.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
24 Analysts

Profitability

Net Income
$-440,240,000.00
Pretax Margin
-15.33%

Debt

Sales & Book Value

Annual Sales
$2.09 billion
Book Value
($1.76) per share

Miscellaneous

Free Float
127,046,000
Market Cap
$31.66 billion
Optionable
Optionable
Beta
0.32

Social Links

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ALNY) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners